Malignant Melanoma | Pharmacor | G7 | 2015
The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Since 2011, three immune checkpoint inhibitors and four BRAF- or MEK-targeted agents have gained regulatory approval for unresectable or metastatic malignant melanoma. Among the most-recent market entrants, anti-PD-1 inhibitors Opdivo (Bristol-Myers Squibb/Ono Pharmaceutical’s nivolumab) and Keytruda (Merck & Co.’s pembrolizumab) are now in the spotlight. Numerous label expansions for currently marketed therapies are expected to further shape the malignant melanoma market, and as emerging combination therapies demonstrate impressive results, the market will become increasingly competitive. Drawing on insights from interviewed thought leaders, this report provides a comprehensive analysis of current treatment of melanoma in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) and a detailed analysis of key therapies in development. The report provides a ten-year annualized sales forecast extending to 2024, based on market-relevant patient populations.
